A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
about
Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: a pooled analysis of seven prospective clinical trialsPhase II study of prolonged ambulatory infusion carboplatin and oral etoposide for patients progressing through hormonal therapy for prostate cancer.Docetaxel plus oral metronomic cyclophosphamide: a phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients.Update on options for treatment of metastatic castration-resistant prostate cancerA phase 2 study of estramustine, docetaxel, and bevacizumab in men with castrate-resistant prostate cancer: results from Cancer and Leukemia Group B Study 90006.Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates.Evolving treatment paradigms for locally advanced and metastatic prostate cancer.Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer.The novel toluidine sulphonamide EL102 shows pre-clinical in vitro and in vivo activity against prostate cancer and circumvents MDR1 resistance.Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group B.Satraplatin for the therapy of castration-resistant prostate cancer.Germline BRCA mutation does not prevent response to taxane-based therapy for the treatment of castration-resistant prostate cancer.Docetaxel-based combination therapy for castration-resistant prostate cancer.Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).Castration-resistant prostate cancer: many treatments, many options, many challenges ahead.Clinical and pharmacokinetic evaluation of satraplatin.Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer.Landmarks in non-hormonal pharmacological therapies for castration-resistant prostate cancer.The evolving role of cytotoxic chemotherapy in the management of patients with metastatic prostate cancer.An aggressive signet ring cell carcinoma of the prostate in a Japanese man.Docetaxel-based regimens, the standard of care for metastatic androgen-insensitive prostate cancer.Genetically engineered Newcastle disease virus for prostate cancer: a magic bullet or a misfit.Rhodamine-123: therapy for hormone refractory prostate cancer, a phase I clinical trial.The evolution of chemotherapy for the treatment of prostate cancer.Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study.Chemotherapy and radiation for prostate cancer
P2860
Q24599547-49EA0945-D82D-4954-9A59-62A2EA026C28Q33366793-CE34582B-FA4A-4B8D-BC69-97D7E4500B4DQ33416977-5FE98D76-DBF4-4F06-877A-854D0ECAD365Q33956051-E79375DE-8C77-445A-A2FB-88AC69B77A74Q34441553-2521098F-0C6D-4C5B-88FA-1883650006C9Q36444444-E3324B6D-8205-4E66-8FC9-F611F022AAC1Q36668260-75CEA7A3-415C-43C9-AC0C-B99E791C0953Q37231510-5C68EE1B-3E84-4276-98C2-940E8A585C03Q37235511-96F2C92B-4289-4A66-A313-44657D8B12C9Q37301691-9BA5C435-0079-48FD-8AD3-550BED48E83CQ37605845-84FBED1F-0642-4F0C-8E55-25F48E116238Q37677557-10B3D6D0-FA60-4A91-9BC7-040456295B84Q37721016-F54A1C27-9827-4CB1-871A-8344526AE3A4Q37950459-5C0C590D-BA02-4F24-9727-C50A107E025FQ37950948-B19F5106-0556-4F14-AA88-DEC1425A369CQ37958009-028181EA-250D-48DA-BC66-EA97DFE09075Q38028012-B68243DC-C4BF-4EA4-BAD0-C4903F8D7698Q38050465-F39C1C06-8A9C-4150-95CE-A4ED90E65809Q38374417-C4070520-468F-4A75-BC82-0DD3E2D8FADAQ39256898-6216E20D-5330-45CC-8A64-6F4322428692Q40340477-F9404005-1991-49FB-96E3-504AEFC8F679Q44319257-4EBB25AB-8000-4E14-9D1F-9A32F5E2E1F1Q45298479-9E1F0196-589B-4E85-8712-C57C0A6900E4Q45943517-A0C1A4F3-3111-4AAA-9AE1-54F1833E4433Q54631608-F0DEC410-9126-477B-B80B-5B248205D6EFQ57112428-E388CA36-9F8B-4A0A-952C-26E5EA4C2462
P2860
A phase II study of estramustine, docetaxel, and carboplatin with granulocyte-colony-stimulating factor support in patients with hormone-refractory prostate carcinoma: Cancer and Leukemia Group B 99813.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
A phase II study of estramusti ...... er and Leukemia Group B 99813.
@ast
A phase II study of estramusti ...... er and Leukemia Group B 99813.
@en
type
label
A phase II study of estramusti ...... er and Leukemia Group B 99813.
@ast
A phase II study of estramusti ...... er and Leukemia Group B 99813.
@en
prefLabel
A phase II study of estramusti ...... er and Leukemia Group B 99813.
@ast
A phase II study of estramusti ...... er and Leukemia Group B 99813.
@en
P2093
P356
P1433
P1476
A phase II study of estramusti ...... cer and Leukemia Group B 99813
@en
P2093
Cancer and Leukemia Group B 99813
Cary Werner
Eric J Small
Nicholas J Vogelzang
Paul A Godley
W Kevin Kelly
P304
P356
10.1002/CNCR.11829
P407
P577
2003-12-01T00:00:00Z